Asia Pacific Transient Protein Expression Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type; Application; End User

The Asia Pacific transient protein expression market is expected to reach US$ 151.9 million by 2027 from US$ 97.4 million in 2019; it is estimated to grow at a CAGR of 5.9% from 2020 to 2027. The market growth in this region is primarily attributed to factors such as the increasing applications of protein expression and growing adoption of precision medicines. However, the high cost of products limits the transient protein expression market growth.

Technological advancements are encouraging the adoption of molecular biology techniques for the development of various therapeutic or treatment modalities. Different therapeutic approaches utilize genomic, transcriptomic information that facilitates the discovery of biomarkers to monitor disease and predict their risks. The use of personalized or precision medicines has dramatically risen due to the wide awareness regarding the genetic variations among people. For instance, mRNA-mediated therapy is used for treating several diseases, as it is associated with decreased immunogenicity, superior translation efficacy, enhanced stability, pharmaceutical safety, and transient protein expression; the therapy is characterized by the expression of only the mRNA, which doesn’t get incorporated in the host genome. Thus, continuous research and development activities, and growing government initiatives to support precision medicine boost are the key factors contributing to the transient protein expression market growth in Asia Pacific.

Recombinant forms of the SARS-CoV-2 spike protein and related viruses have proven difficult to produce in mammalian cells, and the expression processes fails to produce good yields. Researchers have explored new approaches for spike production and purification. For rapid development of full-length SARS-CoV-2 ectodomain, three transient gene expression methods based on polyethylenimine-mediated (PEI-mediated) transfection of CHO or HEK293 cells in suspension culture in chemically-defined media were compared. The current COVID-19 pandemic has produced a huge immediate demand for SARS-CoV-2 RNA/protein-based diagnostic reagents and associated antibodies, putting tremendous stress on the supply and distribution chains. Executing rapid, larger scale production, coupled with the escalation of production in transgenic plants, followed by the transient expression in plant cells may resolve the difficulties induced by shortage. In December 2020, Clover Biopharmaceuticals, China, announced positive clinical results of its Phase 1 trial of its protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants procured from either GSK induce strong immune responses, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in 150 adult and elderly participants.

However, in long run the market has strong potential to boost the growth rate as Asia Pacific is most populated region in the world and where high number of Covid 19 cases detected. Also, the prevalence of other infectious diseases and cancer cases. The impact of the COVID19 pandemic on the regional transient protein expression market is moderate.

Based on product type, the Asia Pacific transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2019, whereas the expression vectors segment is expected to register the highest CAGR during the forecast period.

Based on application, the Asia Pacific transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held the largest market share in 2019, and the segment is anticipated to register the highest CAGR during 2020–2027.

The Asia Pacific transient protein expression market, by end user, is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held the largest market share in 2019; it is further is estimated to register the highest CAGR in the market during the forecast period.

The Ministry of Science and Technology (India), Australian Cluster Observatory, and McKell Institute are among the key secondary sources referred to while preparing the report on the Asia Pacific transient protein expression market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific transient protein expression market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific transient protein expression market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth, offering developed and emerging markets.
• Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.